NCT03661879 - Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 12, 2018

Primary Completion Date

September 5, 2019

Study Completion Date

October 9, 2019

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

DRUG

NNC9204-1706

Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.

DRUG

Placebo (NNC9204-1706)

Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.

Trial Locations (1)

66212

Novo Nordisk Investigational Site, Overland Park